Seasonal allergic rhinitis Respiratory
Conditions
Interventions
Subjects were randomly assigned in an equal ratio to one of the two treatment arms. A stratified randomization was performed according to the outcome of the NPT screening (1st stratum?threshold level
Sponsors
OM Pharma SA (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects must be 18 to 40 years of age, of either sex and any ethnic origin 2. Subjects must have at least a 2 year history of grass pollen induced seasonal allergic rhinitis (documented or reported by the patient) 3. Subjects must have a positive skin prick test response (wheel diameter >3 mm) and/or specific IgE for grass pollen (>0.35 kU/L). 4. Subjects must have a nasal reaction threshold of 10, 000 or less standardized quality units (SQs)/mL grass pollen, performed at the inclusion visit 5. Subjects must be free of any clinically significant disease, other than seasonal allergic rhinitis, which could 6. 6. 6. Subjects must have given written informed consent and must be able to adhere to dose, visits schedule and meet study requirements 7. In females of childbearing potential, the urine pregnancy test must be negative before performing the screening 8. Non-sterile or premenopausal female subjects must be using a medically accepted method of birth control, that is, oral contraceptive, hormonal implant, medically prescribed IUD, or depot injectable during the entire study. A female subject who was not of childbearing potential must have a medical record of being surgically sterile (for example, hysterectomy, and tubal ligation), or be at least 1 year postmenopausal
Exclusion criteria
Exclusion criteria: 1. Subjects who have had an episode of allergic rhinitis in the last two weeks prior to screening 2. Subjects who have had an upper respiratory tract or sinus infection, that required antibiotherapy, or who have had a viral upper respiratory infection, in the last two weeks prior to screening 3. Subjects with asthma who require chronic use of inhaled or systemic corticosteroids (decrease of peak flow > 20% of usual subject value) 4. Subjects with current seasonal (SAR) or perennial (PAR) allergic rhinitis 5. Subjects with known clinical allergic symptoms compatible with sensitization to tree pollens 6. Subjects with clinically significant nasal structural abnormalities (e.g. marked nasal septum deviation, major poliposis) that significantly interfere with nasal air flow 7. Subjects with current evidence of clinically significant haematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disease, or other disease that preclude the subject's participation in the study 8. Subjects with a current history of frequent, clinically significant sinusitis or chronic purulent postnasal drip, or necessitating chronic intake of antibiotherapy 9. Subjects with non-specific nasal reaction (e.g. threshold reached with diluents alone at inclusion) 10. Subjects smoking more than 10 cigarettes/day and/or known to have severe alcohol intake and/or drug addiction 11. Subjects with intolerable symptoms that would make participating in the study unbearable 12. Subjects with a history of anaphylaxis and/or severe local reactions(s) to skin testing with allergens 13. Subjects with a history of hypersensitivity to the study drug 14. Subjects on immunotherapy or desensitization therapy 15. Subjects receiving any medication that might affect the test parameters (oral or topical antihistamines, steroids, antidepressants with antiallergical properties) within 2 weeks before study start (1 month for corticosteroids)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The primary efficacy endpoint was defined as a difference in combined clinical thresholds to allergen nasal provocation test of at least one allergen dose level. The nasal reaction threshold (combined threshold) was reached when at least 2 of the 3 following clinical criteria were fulfilled: 1.1. Five or more sneezes in the first 10 minutes after the challenge, an increase from baseline value (obtained after diluent challenge) of at least 0.5 g of nasal secretions 10 minutes after the challenge, and a decrease from baseline values =40% in PNIF and/or = 30% in MCA 10 minutes after the challenge. at baseline (V1), treatment start(V2) , 29 days (V3) and 30 days (V4) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Objective symptom ratings 2. Subjective symptom ratings by means of a visual analogue scale (VAS) 3. Early and late allergic phase markers (from nasal secretions) at baseline (V1), treatment start(V2) , 29 days (V3) and 30 days (V4) | — |
Countries
Switzerland
Outcome results
None listed